Cytokeratin 8 (CK8) is a high molecular weight B-type cytokeratin, which mainly marks non squamous epithelium. Therefore, it is mainly used for the diagnosis of adenocarcinoma and ductal carcinoma. Squamous carcinoma generally does not express CK8. It has been reported that hepatocellular carcinoma mainly expresses CK8 and CK18. Cytokeratin 18 (CK18), with a molecular weight of 45kda, belongs to low molecular weight type a cytokeratin. It mainly marks all kinds of monolayer epithelium, including glandular epithelium, while stratified squamous epithelium is often negative. It is mainly used for the diagnosis of adenocarcinoma.
Cytokeratin 8 (CK8) is a high molecular weight B-type cytokeratin, which mainly marks non-squamous epithelium. Therefore, CK8 is mainly used to identify adenocarcinoma and ductal carcinoma. Generally, CK8 is not expressed in squamous carcinoma. It has been reported that CK8 and CK18 are mainly expressed in HCC.
Cytokeratin (high molecular weight) can recognize cytokeratin 1, cytokeratin 5, cytokeratin 10 and cytokeratin 14. In normal tissues, cytokeratin (high molecular weight) is mainly expressed in squamous epithelium, ductal epithelium and other stratified epithelium. It’s also expressed in lung squamous cell carcinoma, breast cancer, pancreatic cancer, cholangiocarcinoma and bladder transitional cell carcinoma. This can recognize the basal cells of benign prostatic duct, but it is not expressed in prostate cancer. It is often used in combination with p63 and P504S in the judge of prostate cancer.
Lascia la tua email e seleziona le aree che vuoi seguire per ricevere novita di prodotto, approfondimenti tecnici e promozioni piu pertinenti.
Puoi scegliere le macro-aree Life Science e Diagnostica oppure le singole specializzazioni.
Seleziona uno o piu ambiti di interesse per ricevere comunicazioni piu utili e mirate.
Aggiornamenti su ricerca, strumentazione e applicazioni per il mondo Life Science.
Novita, approfondimenti e promozioni per laboratori diagnostici e flussi operativi.
2025 TEMA Ricerca - All Rights Reserved.